Clinical trials: System Sclerosis
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
This is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of iloprost on the frequency of and relief from symptomatic digital ischemic episodes in subjects with…
- Trial name
- NCT04040322
- Testing
- Iloprost Injection, for intravenous use
- Where
- 30 sites in United States
- Volunteers
- 198 people
- Sponsor
- Civi Biopharma, Inc.
Multiple Sclerosis
Safety of Polyphenon E in Multiple Sclerosis Pilot Study
This study is an open label 6 month study. All subjects will be treated with Polyphenon E (400 mg EGCG twice a day) for six months. The main outcome of this pilot phase will be safety.
- Trial name
- NCT00836719
- Testing
- Polyphenon E
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
Amyotrophic Lateral Sclerosis (ALS)
Extension Study of Participants From SPG302-ALS-001
This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALS-101 with Amyotrophic Lateral Sclerosis (ALS)
- Trial name
- NCT06903286
- Testing
- SPG302
- Where
- 3 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Spinogenix
Multiple Sclerosis
Neurofilament Light Chain ,Chitinase-3 Like-1 Proteins and Plasmacytoid Dendritic Cells in Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune neurodegenerative disease characterized by demyelination and neurodegeneration of the central nervous system (CNS) .
- Trial name
- NCT05451069
- Testing
- Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells
- Volunteers
- 42 people
- Sponsor
- Assiut University
Systemic Sclerosis, Early Systemic Sclerosis Without Clinical Scleroderma and Onset < 2 Years
Optical Coherence Tomography Imaging in Systemic Sclerosis
Systemic sclerosis (SSc) is an autoimmune disorder characterized by early vascular endothelial involvement. SSc is a rare and devastating multi-visceral disease when fibrotic lesions extend to the skin and other tissues (heart…
- Trial name
- OCTISS (NCT04532151)
- Testing
- Non-invasive skin imaging assessment
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis
The primary objective was to evaluate the long-term safety and tolerability of teriflunomide when added to treatment with interferon-β [IFN-β] or glatiramer Acetate [GA] in patients with multiple sclerosis [MS] with relapses.
- Trial name
- NCT00811395
- Testing
- Teriflunomide, Interferon-β [IFN-β], Glatiramer Acetate [GA]
- Where
- 7 sites in United States, Austria and 5 more
- Volunteers
- 182 people
- Sponsor
- Sanofi
Multiple Sclerosis, COVID-19
COVID-19 on Disease Activity in Radiologically Isolated Syndrome Cohort
The Radiologically Isolated Syndrome (RIS) is defined as incidental Magnetic Resonance Imaging (MRI) abnormalities fulfil the criteria for dissemination in space, suggestive of multiple sclerosis.
- Trial name
- VaxiRIS (NCT05387395)
- Testing
- NO intervention
- Where
- France
- Volunteers
- 217 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Amyotrophic Lateral Sclerosis, ALS
RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial
Triumeq is an approved medicine for HIV. The effectiveness of Triumeq in Amyotrophic Lateral Sclerosis (ALS) is being investigated in the Lighthouse II trial.
- Trial name
- Lighthouse III (NCT06658977)
- Testing
- Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)
- Where
- 7 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Macquarie University, Australia
Multiple Sclerosis
The Effect of Task-Oriented Training in Patients With Multiple Sclerosis
It is reported that 85% of MS patients have gait disturbance, 87.9% balance, 35-90% fatigue and 45-60% cognitive problems. Rehabilitation approaches based on the motor control systems model, the plasticity concept, the motor…
- Trial name
- NCT03505294
- Testing
- Task-oriented training
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Gazi University
Systemic Sclerosis
Small Intestinal Mucosal Abnormalities in Systemic Sclerosis Using Capsule Endoscopy
The aim of this prospective study is to determine prevalence and characteristics of small intestinal mucosal abnormalities in 40 patients with systemic sclerosis, using capsule endoscopy.
- Trial name
- sclero-video (NCT00958672)
- Testing
- Endoscopic capsule
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Rouen
Amyotrophic Lateral Sclerosis
Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07095712
- Testing
- nL-TARD-001
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Sporadic and Familial Amyotrophic Lateral Sclerosis
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.
- Trial name
- FB1006 (NCT05923905)
- Testing
- FB1006
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Peking University Third Hospital
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
The Synergistic Effects of AIH and FES in Persons With MS
The purpose of this study is to examine how neuromuscular electrical stimulation (NMES), may synergistically enhance corticospinal excitability in people with relapsing form multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
- Trial name
- NCT06413602
- Testing
- Acute Intermittent Hypoxia, Neuromuscular Electrical Stimulation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shirley Ryan AbilityLab
Multiple Sclerosis
Adderall XR and Cognitive Impairment in MS
This 12 week randomized placebo-controlled study will compare the effects of 10 mg and 20 mg of a mixed amphetamine salt, extended release medication (trade name Adderall XR) to placebo on objective measures of processing speed…
- Trial name
- NCT02676739
- Testing
- Adderall XR
- Where
- 3 sites in Canada
- Volunteers
- 180 people
- Sponsor
- Sarah Morrow
Multiple Sclerosis, Urinary Bladder, Neurogenic
Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Sclerosis
The major part of people with multiple sclerosis (pwMS) experiences Low Urinary Tract Symptoms (LUTS) secondary to neurogenic Low Urinary Tract Dysfunctions (n-LUTDs) during the course of MS, reaching almost 100% after about 10…
- Trial name
- MUSA (NCT05075642)
- Testing
- Initial management of the urinary disorder/s identified during the screening phase
- Where
- Italy
- Volunteers
- 214 people
- Sponsor
- ASP 7 Ragusa
Interstitial Lung Disease With Systemic Sclerosis
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at…
- Trial name
- EVER-ILD 3 (NCT06549231)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- University Hospital, Tours
Relapsing Remitting Multiple Sclerosis
A Study for Patients With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis.
- Trial name
- MINDSET01 (NCT00869986)
- Testing
- dirucotide
- Where
- 6 sites in Bulgaria, Poland and 4 more
- Volunteers
- 218 people
- Sponsor
- Eli Lilly and Company
Optic Neuritis
Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis
The purpose of this study is to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis.
- Trial name
- NCT00355095
- Testing
- Erythropoietin
- Where
- 3 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Multiple Sclerosis
To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis
This is an observational, non controlled, multicentric, prospective study planned to be conducted in 350 subjects diagnosed with multiple sclerosis (MS) in 20 centres of Argentina to identify the predictive factors leading to…
- Trial name
- NCT01079975
- Where
- Argentina
- Volunteers
- 301 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD)
A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with central nervous system autoimmune diseases…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Autoimmune Encephalitis, Stiff Person Syndrome
- Trial name
- NCT07341828
- Testing
- CD20/BCMA-directed CAR-T cells
- Volunteers
- 15 people
- Sponsor
- Huashan Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.